anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Body segments can be defined as the suitable posture positions. Body segments are placed in a way that center of gravity of each segment lies vertically. By this appropriate alignment, instead of excessive muscular activity, stability can be achieved by the body by the use of bone structures and ligament. Hence, in this way body structures experience the decreased tension. Besides the cosmetic effects of high heels, high heels results in increased risk of fall, fracture of bones particularly bones lower extremity, and also the change in normal kinematics of lower limb especially knee joint, and altered weight bearing on medial and longitudinal arches of foot. High heels change the line of gravity and posture of the body. Use of high heels change the posture which is compensated by the changes in different segments of the body like increased planter flexion of ankle as well as the displacements of the trunk and posterior pelvic tilting. The whole body mechanics gets affected in females wearing high heels. The center of gravity get disturbed with the use of high heel shoes. In body alignment, pelvis is known to have key importance. Any alteration in neutral position of pelvis leads to the compensatory altered movements in different regions, while, the segment which is considered to be the most effect is lumber spine.
A 28-year-old patient with severe haemophilia A presented to the emergency department with significant and painful swelling of the left cheek, an extensive haematoma extending from the left ear to the anterior thoracic region, an intraoral haematoma over the soft palate with deviation of the uvula to the right, and complaints of shortness of breath when lying down. Three days prior, his dentist had performed a restoration of the 36 molar under local anaesthesia. Due to pain, the general practitioner had administered an intramuscular injection of a non-steroidal anti-inflammatory drug (NSAID) two days post-procedure. The patient was admitted for treatment with coagulation factors and pain management. Dental procedures and local anaesthesia in patients with a severe coagulation disorder require specific preparatory measures, such as administration of coagulation factors. Collaboration and consultation with a patient's haematologist or haemophilia treatment centre are essential requirements for safe dental care.
The present invention relates to a fusion protein SG-LDP-AE in strengthened genetic engineering, which is prepared by two technical lines: genetic engineering construction and molecule strengthening of the fusion protein. The fusion protein has strong effect on damaging tumor cells. The fusion protein can carry out specific combination with the tumor cells for expressing an epidermal growth factor receptor (EGFR) in vitro. An animal experiment shows that the fusion protein has obvious therapeutic effect on the transplanted liver cancer H22 of a mouse. When tolerable dose of the fusion protein is used, the inhibition ratio can reach to 95.8% (p<0.001). The result shows the characteristics of miniaturization and high efficiency of targeted drugs. The present invention is expected to be a novel targeted drug used for clinical tumor treatment.
Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti-C5 monoclonal antibody eculizumab was the first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at the price of a life-long intravenous fortnightly drug. Additionally, suboptimal response may occur in up to 2/3 of patients with persistent anemia due to incomplete control of intravascular hemolysis, development of upstream C3-mediated extravascular hemolysis (EVH), or concomitant bone marrow failure. Ravulizumab, a longer half-life anti-C5 developed from eculizumab, administered every 8 weeks, improved patient convenience, and reduced pharmacokinetic breakthrough hemolysis (BTH) by establishing more stable anti-C5 concentrations. More recently, several other anti-C5 compounds (crovalimab, pozelimab, tesidolumab, cemdisiran, zilucoplan, and coversin) are on study in clinical trials. Upstream inhibition of complement cascade was also explored with the anti-C3 pegcetacoplan, and with the alternative pathway inhibitors iptacopan (anti-factor B) and danicopan (anti-factor D). These drugs efficiently target EVH and are able to improve anemia and transfusion need in suboptimal responders to anti-C5. The route and schedule of administration (twice weekly subcutaneously for pegcetacoplan and twice or thrice oral daily dosing for iptacopan and danicopan, respectively) are very convenient but pose novel issues regarding adherence. Additionally, both anti-C5 and upstream inhibitors do not resolve the unmet need of pharmacodynamic BTH events due to complement amplifying conditions such as infections, traumas, and surgery. In this review, we will recapitulate PNH physiopathology, clinical presentation, and diagnosis and describe available and developing drugs that will lead to a precision medicine approach for this rare though heterogenous disease.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, immunology and virology. Described is a means for inducing specific immunity against SARS-CoV-2 severe acute respiratory syndrome virus in lyophilized form, containing as the only active component an expression vector based on the genome of the recombinant human adenovirus strain of the 26th serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inserted expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Also presented is a variant of an agent for inducing specific immunity against the SARS-CoV-2 severe acute respiratory syndrome virus in lyophilized form, containing as the only active component an expression vector based on the genome of the recombinant human adenovirus strain of serotype 5, in which the E1 and E3 regions are deleted , with an embedded expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. In addition, a variant of the agent for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 in lyophilized form is described, containing as the only active component an expression vector based on the genome of the recombinant simian adenovirus strain of serotype 25, in which E1 and E3 region, with a built-in expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. In this case, in the particular case of its implementation, the buffer solution of the agent for the reconstituted lyophilized form contains, wt. %: tris from 0.0180 to 0.0338; sodium chloride 0.1044 to 0.1957; sucrose 5.4688 to 10.2539; magnesium chloride hexahydrate from 0.0015 to 0.0028; EDTA from 0.0003 to 0.0005; polysorbate-80 from 0.0037 to 0.0070; water - the rest. In this case, the agent is intended for use intranasally or intramuscularly. Also, the agent can be administered jointly and simultaneously intranasally and intramuscularly.EFFECT: development of reactions of humoral and cellular immune response against SARS-CoV-2 virus in the general population.8 cl, 4 dwg, 6 tbl, 12 ex
BACKGROUND: Success rates in endourological procedures, notably percutaneous nephrolithotomy (PCNL) and ureteroscopy (URS), have demonstrated suboptimal outcomes, leading to more reinterventions and radiation exposure. Recently, the use of intraoperative computed tomography (ICT) scans has been hypothesized as a promising solution for improving outcomes in endourology procedures. With this considered, we conducted a comprehensive systematic review and meta-analysis encompassing all available studies that evaluate the impact of the use of intraoperative CT scans on surgical outcomes compared to conventional fluoroscopic-guided procedures.
METHODS: This systematic review was conducted in accordance with PRISMA guidelines. Multiple databases were systematically searched up to December of 2023. This study aimed to directly compare the use of an ICT scan with the standard non-ICT-guided procedure. The primary endpoint of interest was success rate, and the secondary endpoints were complications and reintervention rates, while radiation exposure was also evaluated. Data extraction and quality assessment were performed following Cochrane recommendations. Data was presented as an Odds ratio with 95%CI across trials and a random-effects model was selected for pooling of data.
RESULTS: A comprehensive search yielded 533 studies, resulting in the selection of 3 cohorts including 327 patients (103 ICT vs 224 in non-ICT). Primary outcome was significantly higher in the experimental group versus the control group (84.5% vs 41.4% respectively, 307 patients; 95% CI [3.61, 12.72]; p<0.00001; I2=0). Reintervention rates also decreased from 32.6% in the control to 12.6% in the ICT group (OR 0.34; 95%CI [0.12,0.94]; p =0.04; I2= 48%), whereas complication rates did not exhibit significant differences. Radiation exposure was also significantly reduced in two of the included studies.
CONCLUSION: This meta-analysis highlights a favorable outcome with intraoperative CT scan use in PCNL procedures, showing a considerable increase in SFR when compared to standard fluoroscopy and nephroscopy. Despite limited studies, our synthesis underscores the potential of ICT scans to significantly reduce residual stones and their consequences for endourology patients, as reinterventions and follow-up ionizing radiation studies.
In one aspect, the disclosure relates to a method for treating or preventing a bacterial infection in a subject, the methods including at least the step of administering a composition including a transition metal and avobenzone to the subject. In one aspect, the transition metal can be present as a transition metal salt such as, for example, ZnSO 4 . In a further aspect, the bacterial infection can be caused by any pathogenic bacteria, including, but not limited to, Gram-positive bacteria such as, for example, methicillin-resistant  Staphylococcus aureus  (MRSA). In one aspect, the compositions can be applied topically in the forms of gels, creams, lotions, sprays, and the like. In any of these aspects, the compositions are non-toxic to mammalian cells. Also disclosed are compositions that can be used to perform the disclosed methods.
<P>PROBLEM TO BE SOLVED: To provide an information processing system managing secret information without leaking it, and allowing effective information provision in reference to the secret information.  <P>SOLUTION: For example, the personal secret information of an information requirement user is stored in a secret information database capable of being accessed by only a management server. The management server applies the secret information to generate a keyword for retrieving an appropriate person of an information providing user, extracts the information providing user on the basis of the generated keyword, and exhibits requesting contents from an information requesting terminal to the information providing user. The information providing user generates a comment according to the exhibited contents, and stores it into a question response database of the management server. The information requesting user accesses the question response database subject to authentication satisfaction in authentication processing of the management server, and acquires the comment of the information providing user.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Described is a novel gene and its encoded secreted tumor antigen, termed BPC-1, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express BPC-1, particularly including prostate cancer and bladder cancer. In human normal tissues, BPC-1 is only expressed in certain tissues of the brain. However, BPC-1 is expressed at high levels in prostate cancer cells and is also expressed in bladder cancer cells. The structure of BPC-1 includes a signal sequence and a CUB domain. BPC-1 protein is secreted. Preliminary experimental evidence suggests that BPC-1 is directly involved in oncogenesis or maintenance of the transformed phenotype of cancer cells expressing BPC-1. BPC-1 also appears to bind specifically to a cellular protein expressed in prostate cancer cells and other cells.
Metal or plastic biliary stents placement under ERCP is a well-established treatment for patients with benign biliary obstruction to relieve jaundice, a palliative treatment for patients with unresectable malignant pancreaticobiliary obstruction and a bridge to surgery for patients with resectable disease. Single or multiple plastic stents are recommended for patients with benign stricture of the common bile duct or malignant stricture if the expected survival is less than 4 months. The main limitation of long time plastic stents is stents occlusion. Biliary plastic stents are changed every 2 to 3 months due to an expected median patency from 77 to 126 days.Metal stents present a lower risk of recurring biliary occlusion, yet high cost and stents occlusion are eventually inevitable. The mechanism of biliary stents occlusion include biliary sludge of the accumulation of bacteria and duodenal biliary reflux .The anti-reflux barrier of Oddi's sphincter disappears after the insertion of biliary stents and the pressure in bile duct lowers the duodenale, which cause the retrograde flow of duodenal material into the biliary ducts. Besides, ordinary biliary plastic stent is short which can also shortens the length of duodenal biliary reflux . Therefore, trying to prevent the duodenal biliary reflux is very important in reducing biliary stents occlusion and it is gradually concerned by clinical researchers. Some studies have showed that plastic stents with antireflux valves can effectively reduce the biliary stent stricture and prolong the stents patency, which means reducing duodenobiliary reflux is surely useful for keeping biliary stent patency.So,we assume to explore an innovatively intraintestinal extended biliary stents with length of 26cm (reformed with nasobiliary tube ) as substitution for ordinary biliary plastic stent to prevent the duodenobiliary reflux by extending the length of duodenal content reflux and avoid the stents shift via suspending in intrahepatic duct. In this study,we will design a multicenter stratified randomized controlled trial to compare the patency of intraintestinal extended biliary stents and ordinary plastic biliary stents in patients with malignant or benign biliary obstruction respectively and evaluate the effect of intraintestinal extended biliary stents for the prevention of duodenobiliary reflux.

This prospective study will be performed at 6 tertiary hospitals in China.The investigators will recruit patients according to admission criteria and exclusion criteria.The patients stratified by malignant and benign biliary obstruction will be randomized (at a 1:1 ratio) to intraintestinal extended biliary stents group (experimental group) and ordinary plastic biliary stents group (control group).The experimental groups will be placed the intraintestinal extended biliary stents in intrahepatic bile duct in ERCP. The control group will be placed ordinary plastic biliary stents in ERCP. The primary endpoint is the duration of stent patency and the rate of stent occlusion.The secondary outcomes include the mortality of each group、adverse events and the rate of technical success.
Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
Infants will be randomized to receive infant massage or not. Infant massage will be performed three times a day (10 minutes per session) until they reach the 35th week of post-conceptional age (35+6) by the two departmental physical therapists (ADP and ADV).
PURPOSE:To inexpensively prepare the subject peptide by adjusting the pH of a milk raw material containing kappa-casein glycomacropeptide to a specific value and subsequently subjecting the treated raw material to an ultrafiltration treatment and a concentration treatment with an ultrafiltration membrane having a prescribed fractionation mol.wt. CONSTITUTION:A milk raw material (e.g. cheese whey or whey protein concentrate) containing kappa-casein glycomacropeptide is dissolved in water and adjusted to a pH of <4 with hydrochloric acid, etc. The adjusted solution is subjected to an ultrafiltration treatment using an ultrafiltration membrane having a fractionation mol.wt. of 10000-50000 to give a penetration solution. The penetration solution is concentrated with an ultrafiltration membrane having a fractionation mol.wt. of <=50000 to give the kappa-casein glycomacropeptide. The kappa-casein glycomacropeptide useful as a food raw material for preventing obesity, an infection preventing agent against influenza virus, etc., can be thereby prepared readily in a large amount in a high purity.
The invention relates to camel blood polypeptide with the functions of reducing blood pressure and blood fat and a preparation method thereof. The method takes camel blood as a raw material, and the camel blood polypeptide enzymolysis liquid is obtained through enzymolysis and filtration. And (3) carrying out adsorption separation by using a polyamide and macroporous adsorption resin column chromatography combined technology, eluting by using a 50-95% ethanol solution, and drying to obtain the purified camel blood polypeptide with the functions of reducing blood pressure and blood fat. The content of the prepared camel blood polypeptide product is more than 85 percent, and the recovery rate is more than 75 percent. The invention combines polyamide and macroporous adsorption resin to fully exert the advantages of polyamide and macroporous adsorption resin, makes up for the defects, and prepares the camel blood polypeptide with higher purity, stronger blood pressure reduction and blood fat reduction activity. The process has the advantages of simple operation, good selectivity, convenient column regeneration, long service cycle, low operating cost and the like, can meet the requirements of industrial production, and has good economic and social benefits and wide application prospect.
PROBLEM TO BE SOLVED: To obtain a new hair growing and restoring agent having an excellent hair-growing effect and a stability capable of sufficiently tolerating in using for a long period of time by using an extract obtained from a specific plant belonging to the family Labiatae. SOLUTION: This agent is an extract obtained by extracting deucas cephalotes of a vegetation belonging to the genus deucas, family dabiatae originally growing and distributing at lowlands in a Nepal area with a water-soluble organic solvent or water-soluble organic solvent containing water. The amount of the extract containing in this hair grower is 0.001-10wt.%, particularly 0.05-5wt.%. It is preferable to include a vasodilator for peripheral blood vessel of skin in the hair grower. As the vasodilator for peripheral blood vessel of skin, e.g. carpronium chloride, benzeyl nicotinate, vitamin E, vitamin E acetate, etc. are illustrated. This hair grower is possible to prepare in dosage forms such as e.g. hair tonic, shampoo, rinse, pomade, hair lotion, etc.
TBI patients suffer from a host of cognitive and behavioral deficits that requires a comprehensive therapeutic approach to be effective at improving self-regulation and everyday function. These deficits can affect a number of critical aspects of individual performance such as awareness, emotional regulation, and self-efficacy. As an alchemy, these serve to be instrumental to TBI patients' emotional regulation capability, and serve as complements to overall satisfactory executive functioning. Efforts have been made in therapeutics to supersede barriers to improving these factors in the form of interventions. Those observed in history had required considerable resources, evident in the apparent high cognitive load and by limits to their effective implementation, wide dissemination and, ultimately, their potential benefit to TBI patients. At present, it is fundamental to explore the benefits of an intervention promising a favorable effect on both attention and present moment awareness (Aim 1), effectiveness in developing emotional regulation and everyday life function (Aim 2), and structured to permit investigation of the functional and structural neural effects on attention (Aim 3). This hypothesis aims to prove these attributes are central to the development of adaptive self-monitoring and self-regulation skills that can be used in a real life environment. The study results will provide valuable information that will ultimately support the refinement of an effective intervention that can have a real impact on patients' ability to improve quality of life, community integration, and supporting an active lifestyle. In addition, acquired neuroimaging will aid in analyzing the effect of the intervention on brain function which will allow for a more established comprehension of the underlying mechanisms driving the benefits, permitting improved design of an effective therapeutic intervention for TBI patients.
BACKGROUND: Otitis media (OM) is the most frequent and complex middle ear condition with multifactorial etiology including genetic predisposition. OM depicts a variable clinical spectrum, leading to speech, developmental delay, and hearing loss. Here, we report the clinical and genetic findings of chronic suppurative otitis media (CSOM) segregating in a six-generation consanguineous Pakistani family PKOM08.
METHODS: Clinical evaluations, including audio and tympanometry, were conducted to assess OM manifestation and their impact on hearing function. Exome sequencing was performed to identify potential genetic variants underlying CSOM in the study participants.
RESULTS: Clinical evaluation of participating individuals revealed varying degrees of disease severity, with mild to moderate hearing loss. All the affected individuals had CSOM with no other apparent comorbidity. Whole exome followed by Sanger sequencing revealed two rare heterozygous variants [c.1867C>T, p.(Pro623Ser) and c.11015G>A, p.(Arg3672Gln)] of BSN gene in most of the affected individuals of family PKOM08. BSN encodes a scaffold bassoon protein involved in synaptic vesicle trafficking. The identified variants replaced evolutionary conserved amino acid residues in the encoded protein and are predicted to impact the ionic interactions in the secondary structure.
CONCLUSION: A deep intronic variant of BSN has been previously implicated in the etiology of childhood ear infections. Our study further supports a link between BSN-impaired function and ear infection and CSOM in children.
This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.